David Apelian - 31 Jan 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
Interim CEO, Director
Signature
/s/ David Apelian
Issuer symbol
N/A
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 20:12:19 UTC
Previous filing
18 Aug 2022
Next filing
06 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +170,000 $0.000000 170,000 31 Jan 2023 Common Stock 170,000 $1.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 113,900 shares upon the earlier to occur of (i) on the six-month anniversary of December 14, 2022 or (ii) the Company's appointment of a full-time non-interim Chief Executive Officer, and as to the remaining 56,100 shares in six equal monthly installments measured from December 14, 2022, subject to the Reporting Person's continuous service as of each such date.